{
    "eid": "2-s2.0-85114788897",
    "title": "Intradermal ChAdOX1 vaccine following two coronavac shots: A case report",
    "cover-date": "2021-09-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Immunology",
            "@code": "2403",
            "@abbrev": "IMMU"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Drug Discovery",
            "@code": "3002",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "ChAdOx1-S",
        "CoronaVac",
        "COVID-19 vaccines",
        "Intradermal injections",
        "Intramuscular injections"
    ],
    "authors": [
        "Ekachai Singhatiraj",
        "Krit Pongpirul",
        "Anan Jongkaewwattana",
        "Nattiya Hirankarn"
    ],
    "citedby-count": 5,
    "ref-count": 18,
    "ref-list": [
        "Effectiveness of an inactivated SARS-CoV-2 vaccine in chile",
        "Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: An immunological study",
        "Immunogenicity and reactogenicity of bnt162b2 booster in chadox1-s-primed participants (combivacs): A multicentre, open-label, randomised, controlled, phase 2 trial",
        "Intradermal vaccination: A potential tool in the battle against the COVID-19 pandemic?",
        "Immunogenicity and safety of reduced-dose intradermal vs intramuscular influenza vaccines: A systematic review and meta-analysis",
        "Pseudotype neutralization assays: From laboratory bench to data analysis",
        "Studies on the level of neutralizing antibodies produced by inactivated COVID-19 vaccines in the real world",
        "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, bbibp-corv: A randomised, double-blind, placebo-controlled, phase 1/2 trial",
        "Safety and immunogenicity of a DNA SARS-CoV-2 vaccine (zycov-d): Results of an open-label, non-randomized phase i part of phase i/ii clinical study by intradermal route in healthy subjects in india",
        "Safety and immunogenicity of ino-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, phase 1 clinical trial",
        "Tolerability, safety and immunogenicity of intradermal delivery of a fractional dose mrna-1273 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy",
        "Immunogenic potential of DNA vaccine candidate, zycov-d against SARS-CoV-2 in animal models",
        "Immunogenicity of a DNA vaccine candidate for COVID-19",
        "Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals",
        "Thrombocytopenia and splenic platelet directed immune responses after intravenous chadox1 ncov-19 administration",
        "The adjuvant gla-af enhances human intradermal vaccine responses"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60020543",
            "affilname": "Bumrungrad International Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60020543",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Pathum Thani",
            "@id": "60011947",
            "affilname": "Thailand National Center for Genetic Engineering and Biotechnology",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60011947",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Baltimore",
            "@id": "60006183",
            "affilname": "Johns Hopkins Bloomberg School of Public Health",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006183",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": []
}